Over the last decades, clinicians have aimed to design non-invasive, clinically useful instruments, to accurately measure and monitor disease activity in inflammatory bowel disease (IBD). To-date, multiple indices exist, some of which have been validated. In fact, researchers have been moving away from the Crohn's Disease Activity Index more towards patient-reported outcomes (PROs) and objective measures of disease, such as findings from endoscopy. PROs can be assessed for example by the SIBDQ, the short form of the IBDQ, a quality of life measure. It correlates well with disease activity indices. A lesser known tool for symptom assessment is the Dudley IBD Symptom Questionnaire (DISQ), a brief questionnaire which asks the patient to grade the severity of fifteen common symptoms on a 5 point scale. The DISQ is fast to complete without physicians input and was designed in 1994 for point-of-care symptom monitoring in both Crohn's disease and ulcerative colitis patients. The DISQ is known to correlate well with the CDAI and has recently been validated for monitoring bowel symptoms in patients with spondyloarthropathies. The aim of this prospective study was therefore to evaluate the correlation between the DISQ and the SIBDQ, in patients with Crohn's disease and ulcerative colitis, as part of a larger project, entitled ALIVE: Adherence and Long-term IBD Value-added Effectiveness. For this prospective observational assessment, patients with a confirmed diagnosis of either Crohn's Disease or ulcerative colitis were recruited consecutively from the outpatient IBD clinic at a large Mid-Atlantic Tertiary referral center. Following consent, the patients were given the relevant questionnaires for completion- the SIBDQ and DISQ. The DISQ lists 15 IBD symptoms which the patients rate the severity of, from 1 (not present) to 5 (most severe). The SIBDQ consists of 10 questions that ask patients to rate how bothersome symptoms are, as a result of their IBD, from 1 (all of the time) to 7 (no trouble). The DISQ range is 15 to 75, whereby a lower score indicates better symptom control, and the SIBDQ range is 10 to 70, where higher scores indicate better symptom control. Data were analysed using SPSS v 17.0. A Spearman's rho correlation coefficient was used for the analysis. To date, a total of 78 subjects have enrolled, and are included in this analysis. The population is mostly young (mean age of 39), females (68%) with equal numbers of subjects with Crohn's and ulcerative colitis. The average SIBDQ score is 45.8, with an average DISQ of score of 26. A spearman rho correlation between the DISQ and SIBDQ scores was found to be −0.292, P = 0.005. The association between the 2 PRO measures, the DISQ and SIBDQ, was found to be a moderate negative association. The negative association was predicted as one instrument a low score reflects fewer symptoms (DISQ), whereas on the other instrument a high score reflects fewer symptoms. Both instruments are quick and simple point-of-care instruments to assess severity of symptoms by the patient. Further testing of both instruments is warranted.